Breakthrough in US - NewYork Presbyterian chooses DrugLog®
NewYork Presbyterian has, after extensive investigation, chosen DrugLog® to control the returns of narcotic drugs. The agreement comprises a total of 5 DrugLog® units. Installation will take place during the second quarter of 2019.
NewYork Presbyterian (NYP) - one of America's most prestigious hospital group with 7 hospitals in Manhattan, New York - has after a comprehensive evaluation chosen to order a total of 5 DrugLog® units for its New York facilities. DrugLog® will be used to verify that drugs returned from the operating room are not replaced or tampered with. The DrugLog® devices will be a part of the NYP's Drug Diversion Prevention Program. Before NYP decided on DrugLog®, they carried out a comprehensive evaluation of all systems available on the market for screening of returned drugs.
CEO Mats Högberg comments: “We are extremely proud that NYP chooses to implement DrugLog® in its program to prevent Drug Diversion. This is a huge breakthrough for DrugLog® and Pharmacolog and means tremendous business opportunities for us in North American market. It has been a long process, much due to the fact that NYP chose to carry out extensive testing of all systems on the market, before finally deciding on DrugLog®. We have worked long-term and purposefully towards the US market and the team has done an outstanding job in establishing this collaboration.”
For more information contact:
Mats Högberg, CEO
Email: mats.hogberg@pharmacolog.com
Phone: +46 70-546 50 21
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on April 1st 2019 at 08:30.
About Pharmacolog AB
Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company's first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog's long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at www.pharmacolog.com. The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.
